IFP Advisors’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.5K Sell
796
-18
-2% -$260 ﹤0.01% 3307
2026
Q1
$11.8K Sell
814
-222
-21% -$3.18K ﹤0.01% 3074
2025
Q4
$14.8K Buy
1,036
+822
+384% +$8.07K ﹤0.01% 2872
2025
Q3
$1.69K Buy
214
+49
+30% +$349 ﹤0.01% 3768
2025
Q2
$1.32K Sell
165
-11,546
-99% -$74.5K ﹤0.01% 4097
2025
Q1
$95.6K Sell
11,711
-239
-2% -$2.21K ﹤0.01% 1553
2024
Q4
$113K Sell
11,950
-875
-7% -$9.1K ﹤0.01% 1411
2024
Q3
$137K Sell
12,825
-9,695
-43% -$106K ﹤0.01% 1273
2024
Q2
$223K Buy
22,520
+208
+0.9% +$2.13K 0.01% 991
2024
Q1
$263K Buy
22,312
+684
+3% +$8.75K 0.01% 865
2023
Q4
$307K Buy
21,628
+1,525
+8% +$17.3K 0.01% 760
2023
Q3
$244K Sell
20,103
-15,278
-43% -$197K 0.01% 874
2023
Q2
$444K Sell
35,381
-409
-1% -$4.85K 0.02% 697
2023
Q1
$591K Sell
35,790
-1,184
-3% -$14.6K 0.03% 542
2022
Q4
$610K Buy
36,974
+5,381
+17% +$60.6K 0.02% 806
2022
Q3
$519K Buy
31,593
+806
+3% +$8.98K 0.01% 912
2022
Q2
$505K Hold
30,787
0.02% 850
2022
Q1
$505K Buy
30,787
+18,096
+143% +$170K 0.02% 850
2021
Q4
$143K Buy
12,691
+2,091
+20% +$23.3K ﹤0.01% 1111
2021
Q3
$102K Sell
10,600
-1,578
-13% -$16.1K ﹤0.01% 1289
2021
Q2
$118K Buy
12,178
+198
+2% +$1.93K ﹤0.01% 1161
2021
Q1
$119K Buy
11,980
+11,268
+1,583% +$174K ﹤0.01% 1089
2020
Q4
$15K Buy
712
+558
+362% +$11.4K ﹤0.01% 1898
2020
Q3
$2K Buy
+154
New +$2.25K ﹤0.01% 2474
2019
Q1
Sell
-21
Closed 2714
2018
Q4
$0 Hold
21
﹤0.01% 3645
2018
Q3
$0 Sell
21
-69
-77% -$965 ﹤0.01% 3890
2018
Q2
$1K Buy
90
+69
+329% +$1.04K ﹤0.01% 3719
2018
Q1
$0 Hold
21
﹤0.01% 3774
2017
Q4
$0 Sell
21
-1,200
-98% -$16.5K ﹤0.01% 3899
2017
Q3
$18K Sell
1,221
-979
-45% -$13K ﹤0.01% 2662
2017
Q2
$22K Buy
+2,200
New +$17.7K ﹤0.01% 2519
2016
Q4
Sell
-200
Closed -$1K 4032
2016
Q3
$1K Hold
200
﹤0.01% 3718
2016
Q2
$1K Buy
+200
New +$1.4K ﹤0.01% 3612

IFP Advisors's FOLD Position: Q2 2026 in Review

IFP Advisors reduced its Amicus Therapeutics (FOLD) stake by 2.2% in Q2 2026, selling an estimated $260 and leaving 796 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3307.

IFP Advisors first reported a position in FOLD in Q2 2016 and has held it in 33 quarters since. The position peaked at $610K in Q4 2022. 1 fund tracked by Wall St. Rank holds FOLD as of Q2 2026.

  • IFP Advisors held 796 shares of Amicus Therapeutics worth $11.5K as of Q2 2026.
  • IFP Advisors sold 18 Amicus Therapeutics shares in Q2 2026, an estimated $260.
  • Amicus Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3307 holding.
  • IFP Advisors first reported a position in Amicus Therapeutics in Q2 2016 and has held it in 33 quarters since.
  • IFP Advisors's Amicus Therapeutics position peaked at $610K in Q4 2022.
  • 1 fund tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.